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ABSTRACT 
 
Background: Relative risk reduction with statin therapy has been consistent across nearly all 
subgroups studied to date. However, in analyses of two randomized controlled primary 
prevention trials (ASCOT and JUPITER), statin therapy led to a greater relative risk reduction 
among a subgroup at high genetic risk. Here, we sought to confirm this observation in a third 
primary prevention randomized controlled trial. Additionally, we assessed if those at high 
genetic risk had a greater burden of subclinical coronary atherosclerosis. 
Methods: We studied participants from a randomized controlled trial of primary prevention with 
statin therapy (WOSCOPS, n=4,910) and two observational cohort studies (CARDIA and 
BioImage, n=1,154 and 4,392). For each participant, we calculated a polygenic risk score (PRS) 
derived from up to 57 common DNA sequence variants previously associated with coronary 
heart disease (CHD). We compared the relative efficacy of statin therapy in those at high genetic 
risk (top quintile of PRS) versus all others (WOSCOP)S as well as the association between the 
PRS and coronary artery calcification (CARDIA) and carotid artery plaque burden (BioImage). 
Results: Among WOSCOPS trial participants at high genetic risk, statin therapy was associated 
with a relative risk reduction of 44% (95% CI, 22%-60%; P < 0.001) whereas in all others, 
relative risk reduction was 24% (95% CI 8%-37%; P = 0.004) despite similar LDL cholesterol 
lowering. In a study-level meta-analysis across the WOSCOPS, ASCOT, and JUPITER primary 
prevention, relative risk reduction in those at high genetic risk was 46% versus 26% in all others 
(P for heterogeneity = 0.05). Across all three studies, the absolute risk reduction with statin 
therapy was 3.6% (95% CI, 2.0%-5.1%) among those in the high genetic risk group and was 
1.3% (95% CI, 0.6%-1.9%) in all others. Each standard deviation increase in the polygenic risk 
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score was associated with 1.32-fold (95% CI, 1.04-1.68) greater likelihood of having coronary 
artery calcification and 9.7% higher (95% CI, 2.2-17.8%) burden of carotid plaque. 
Conclusions: Those at high genetic risk have a greater burden of subclinical atherosclerosis and 
derive greater relative and absolute benefit from statin therapy to prevent a first CHD event. 
Clinical Trial registration: WOSCOPS was carried out and completed prior to the requirement 
for clinical trial registration. BioImage: NCT00738725 
(https://www.clinicaltrials.gov/ct2/show/NCT00738725). CARDIA: NCT00005130 
(https://clinicaltrials.gov/ct2/show/NCT00005130). 
 
Key Words:  primary prevention, statin, human genetics, genetic polymorphism, and coronary 
artery calcification
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CLINICAL PERSPECTIVE 
What is New? 
 A recent analysis of primary prevention statin trials surprisingly suggested those at high 
genetic risk for coronary heart disease (CHD) derive greater relative benefit from statin 
therapy. 
 We now developed an expanded genetic risk score for CHD with 57 SNPs to identify 
individuals at high genetic risk. 
 We now show in an independent study (WOSCOPS) statin therapy was associated with a 
relative risk reduction of 44% for CHD among those at high genetic risk versus 24% 
among all others. 
 Additionally, we observe that those at high genetic risk have an increased burden of 
atherosclerosis in both coronary and carotid arteries. 
What Are the Clinical Implications? 
 Stratifying by genetic risk may identify a subset of adults who have a greater burden of 
subclinical atherosclerosis and derive the greatest benefit from statin therapy to prevent a 
first CHD event.   
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INTRODUCTION 
Coronary heart disease (CHD) is a complex, chronic disease responsible for about 7 million 
deaths worldwide in 2010.1 Statin therapy reduces the risk of a first coronary event.2, 3 Effect size 
as measured by relative risk reduction is approximately 20% per 1.0 mmol/L reduction of low 
density lipoprotein (LDL) cholesterol and has been consistent across nearly all subgroups 
defined by clinical and biochemical measures.2, 4 However, if statin therapy was more efficacious 
in one subgroup versus another, this might impact decisions regarding who gets prescribed statin 
therapy in the primary prevention setting.  
We recently reported that those at high genetic risk, defined as the top quintile of a 27-
SNP polygenic risk score for CHD, derived greater relative risk reduction from statin therapy 
compared with all others.5 In two primary prevention trials (ASCOT-LLA: Anglo-Scandinavian 
Cardiac Outcomes Trial – Lipid-Lowering Arm6 and JUPITER: Justification for the Use of 
Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin7), this higher relative benefit 
from statin therapy was observed despite similar levels of LDL cholesterol lowering between 
those at high genetic risk and all others. 
The present study had two main goals: first, to test in a third statin trial if statin treatment 
confers a greater relative risk reduction for a first coronary event in those at high genetic risk, as 
assessed by an expanded 57-SNP polygenic risk score, compared to all others; second, to test if 
there is a greater burden of subclinical coronary atherosclerosis present in those at high genetic 
risk compared to all others.  
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METHODS 
Cohort Descriptions 
The WOSCOPS (West of Scotland Coronary Prevention Study) trial has been described 
previously.8, 9 In brief, WOSCOPS was a randomized controlled trial of 6,595 men (45-64 years) 
with hypercholesterolemia but without a history of myocardial infarction, allocated to pravastatin 
40mg daily versus placebo to prevent coronary events. Genetic data were available in 4,892 men. 
Long-term WOSCOPS results beyond the study’s end were included to assess the durable effects 
of primary preventive statin therapy by genetic risk. Results were also available from a prior 
analysis5 that included a subset of 6,978 individuals with genetic data from ASCOT-LLA, a 
randomized trial of atorvastatin 10mg daily versus placebo in those with hypertension but 
without cardiovascular disease, and 8,769 individuals with genetic data from JUPITER, a 
randomized trial of rosuvastatin 20mg daily versus placebo in those with no history of 
cardiovascular events but elevated C-reactive protein. 
 In two observation cohorts (CARDIA and BioImage), we explored a potential reason for 
the greater clinical benefit of statin therapy in those at high genetic risk. We hypothesized that 
individuals at high genetic risk carried a greater burden of subclinical atherosclerosis. We 
assessed the association of a high genetic risk status with subclinical atherosclerosis in two 
vascular beds in those without clinical CHD. The CARDIA (Coronary Artery Risk Development 
in Young Adults) study (NCT00005130) is an observational study of cardiovascular risk factors 
in 5,115 young adults (18-30 years at baseline, 1989-1990) as previously described.10, 11 Of these 
participants, 1,154 European ancestry individuals without CHD at baseline, available genetic 
data and coronary arterial calcification (CAC) assessment at the 15-year follow-up were included 
in analyses. The BioImage study (NCT00738725) is a multi-ethnic, observational study aimed at 
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characterizing subclinical atherosclerosis in 6,699 US adults (55-80 years at baseline, 2008-
2009) at risk for, but without, clinical atherosclerotic cardiovascular disease.12, 13 As current 
genome-wide association effect estimates for coronary heart disease are most robust in those of 
European ancestry14, we focused on the 4,929 individuals of European ancestry. Of those 
individuals, 4,392 with both genetic data available and carotid plaque assessment were included 
in analyses. In WOSCOPS, CARDIA, and BioImage, participants were not screened for familial 
hypercholesterolemia, a monogenic disorder associated with increased risk of premature CHD 
events. Each trial was approved by institutional review boards, all subjects gave their informed 
consent, and the procedures that were followed were in accordance with institutional guidelines. 
 
Polygenic Risk Score 
Genome-wide association analyses have identified 67 single nucleotide polymorphisms (SNPs) 
across the genome independently associated with CHD (Supplementary Table 1).14-16 We 
recently showed that an expanded set of SNPs compared to a polygenic risk score comprised of 
27 SNPs provided modestly improves risk discrimination.17 Fifty-seven of these variants were 
genotyped among WOSCOPS participants using the Illumina Metabochip18 and included in 
analyses. Thirteen variants were directly genotyped among CARDIA participants using the 
Affymetrix Human SNP Array 6.0 and another 25 proxy variants available through statistical 
imputation. CARDIA genotypes were downloaded from the NIH dbGAP data repository 
(accession phs000613.v1.p2). Fifty-nine variants were directly genotyped among BioImage 
participants using the Illumina HumanExome Beadchip19 and an additional four proxy variants 
(r2 > 0.8) available through statistical imputation.  
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 A polygenic risk score was constructed by weighting the total number of risk alleles by 
their effects (log of the odds ratios) of CHD risk from the published literature. Incremental scores 
from missing genotypes in individuals were imputed based on the allele frequency in each 
cohort. To account for the differences in the numbers of variants per cohort, a normalized 
polygenic risk score (mean = 0, standard deviation = 1) was created per cohort (Supplementary 
Figure 1). 
 
Outcomes 
The primary outcome for the WOSCOPS analysis was nonfatal myocardial infarction or death 
from CHD.8 In WOSCOPS we also studied change in LDL cholesterol from baseline; on-
treatment LDL cholesterol was obtained one year after study drug initiation.  
An exploratory analysis focused on subclinical atherosclerosis - total CAC quantity by 
the Agatston method in CARDIA and total carotid plaque burden in BioImage.20 In the CARDIA 
study, CAC was assessed by electrocardiographic-gated electron beam CT (Imatron C-150, GE 
Imatron, San Francisco, CA) or multidetector CT (GE LightSpeed, GE Healthcare, Little 
Chalfont, UK; or Siemens VZ, Siemens Healthcare, Erlangen, Germany) at the 15 year-follow-
up (33-45 years, 2000-2001).11 In BioImage, carotid plaque was ascertained using the Philips 
iU22 carotid ultrasound system (Philips Healthcare, Bothell, Washington) interpreted by at the 
University of Copenhagen (Copenhagen, Denmark) as described previously.12, 21 If carotid 
plaque was present based on local carotid intima media thickness, it was quantified using the 
Philips QLAB-VPQ software and carotid plaque burden was the sum of all areas of carotid 
plaque from the proximal common carotid artery to the distal internal carotid artery. 
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Statistical Analysis 
Within each cohort, we defined high genetic risk as individuals in the top quintile of the 
distribution of polygenic risk score. Among placebo-treated participants in WOSCOPS, we first 
used a Cox proportional hazards model to determine if polygenic risk score (per standard 
deviation, and high genetic risk versus all others) associated with risk of developing incident 
nonfatal myocardial infarction or death due to CHD. The models were adjusted for age, sex, 
diabetes mellitus status, smoking status, baseline LDL cholesterol, baseline HDL cholesterol, 
systolic blood pressure, antihypertensive medication status, and family history of myocardial 
infarction or stroke. Sex was not used as a covariate in WOSCOPS as all participants were male. 
Higher order terms for PRS were not significantly associated with outcome and the linear 
assumption was not violated. Next, we stratified participants in two groups (high genetic risk, all 
others) and tested the difference in relative risk reduction with statin therapy versus placebo in 
each subgroup. Analysis of Schoenfeld residuals demonstrated similar proportionality across the 
follow-up time.  
 To determine the confidence interval of the absolute risk reduction from statin therapy for 
each polygenic risk score group, we calculated the standard error of the absolute reduction for 
each group as 𝑆𝐸𝐴𝑅𝑅 =
√(
𝑎
𝑛1
) (1 −
𝑎
𝑛1
)
𝑛1
⁄ +
(
𝑐
𝑛2
) (1 −
𝑐
𝑛2
)
𝑛2
⁄  where 𝑎 is statin-treated 
individuals who had events, 𝑛1 is all statin-treated individuals, 𝑐 is placebo-treated individuals 
who had events, and 𝑛2 is all placebo-treated individuals. A chi square test for heterogeneity was 
used to test the differences in absolute risk reduction from statins between those at high genetic 
risk versus all others. 
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 In order to summarize all currently available data across primary prevention trials, we 
performed a study-level meta-analysis combining the present study results with those published 
earlier from the JUPITER and ASCOT-LLA trials5. The analyzed outcome was the primary 
outcome for each primary prevention trial. Effect estimates for high genetic risk versus all others 
was combined using a fixed-effects meta-analysis. A chi-square test for heterogeneity was used 
to compare the proportional risk reductions between the meta-analyzed effect estimates as 
previously described.22 
 In two population-based cohort studies, we tested whether prevalent subclinical 
atherosclerosis differed between those at high genetic risk versus all others. Given the younger 
age of CARDIA participants and a consequential lower prevalence of individuals with any CAC, 
a dichotomous outcome variable (CAC>0 versus CAC=0) was used in in CARDIA. We 
determined whether two predictors (polygenic risk score as a continuous variable or a 
dichotomized high genetic risk versus all others) was associated with CAC using multivariate 
logistic regression in CARDIA. We similarly tested whether polygenic risk score was associated 
with prevalent carotid plaque in BioImage. The outcome variable was the natural log 
transformation of total bilateral carotid plaque + 1. The models were adjusted for age, sex, 
diabetes mellitus status, smoking status, LDL cholesterol, HDL cholesterol, systolic blood 
pressure, antihypertensive medication status, and family history of CHD.  
 All tests were two-tailed with alpha threshold of 0.05. Statistical analyses were conducted 
in R v3.2.1 (R Foundation, Vienna, Austria).  
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RESULTS 
The mean length of follow-up for WOSCOPS participants in trial was 4.8 years (SD, 0.7 years) 
for both placebo and statin groups, and out of trial was 8.7 years (SD, 2.6 years) in the placebo 
group and 8.9 years (SD, 2.4 years) in the statin-treated group; baseline characteristics by genetic 
risk (Table 1) and by randomized treatment groups (Supplementary Table 2) are presented. 
Individuals at high genetic risk (top quintile of polygenic risk scores) were more likely to report 
a family history of CHD (7% vs 5%; P = 0.004) and were less likely to be current smokers (40% 
vs 45%, P = 0.006) compared to all others whereas there was no difference in other baseline 
characteristics including treatment allocation. In placebo-treated WOSCOPS participants, 
predicted 10-year risks for atherosclerotic cardiovascular disease (calculated using ACC/AHA 
pooled cohort equations) were similar across quintiles of polygenic risk score (ACC/AHA 
pooled cohort equations) were similar (Supplementary Table 3). 
 Among those allocated to placebo, those at high genetic risk were at increased risk for a 
first CHD event (HR 1.62; 95% CI, 1.29-2.05; P < 0.001) after adjustment for traditional 
cardiovascular risk factors (Table 2) (Supplementary Figure 2, Supplementary Table 4). 
Furthermore, among placebo-treated participants in WOSCOPS, a one SD increase in polygenic 
risk score was associated with a 25% increased risk in incident CHD (HR 1.25; 95% CI, 1.20-
1.35, P <0.001). Association of polygenic risk score with CHD did not vary between those with 
and without a self-reported family history of CHD (P for interaction = 0.47) (Supplementary 
Table 5). The mean baseline LDL cholesterol was 192 (SD, 17.5) mg/dl in the high genetic risk 
group and 192 (SD, 17.3) mg/dl among all others (P = 0.4).  
 Among those at high genetic risk, statin therapy reduced risk for a first CHD event by 
44% (HR 0.56; 95% CI, 0.40-0.78; P < 0.001) whereas statin therapy reduced risk by 24% 
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among all others (HR 0.76; 95% CI, 0.63-0.92; P = 0.004). Absolute risk reduction with statin 
therapy was 7.9% (95% CI, 3.4%-12.4%) among those at high genetic risk whereas it was 2.7% 
(95% CI, 0.7%-4.7%) among all others during the 13-year follow-up (P for heterogeneity = 0.04) 
(Figure 1). Thus, the number needed to treat (NNT) to prevent one coronary event was 13 
among high genetic risk participants and 38 among all others (Table 3). The degree of LDL 
cholesterol reduction achieved with statin treatment was similar in the high genetic risk group (-
44 mg/dL, 22.9% reduction) compared to all others (-43 mg/dL, 22.2% reduction) (P = 0.52).  
 We performed a meta-analysis combining the results of this study with those published 
earlier from JUPITER and ASCOT-LLA (5). With all three studies combined, statin therapy 
reduced risk for a first CHD event by 46% (HR 0.54; 95% CI, 0.41-0.71; P <0.001) whereas 
statin therapy reduced risk by 26% among all others (HR 0.74; 95% CI, 0.63-0.86; P  <0.001) (P 
for heterogeneity = 0.05) (Figure 2). Across all three studies, the absolute risk reduction with 
statin therapy was 3.6% (95% CI, 2.0%-5.1%) among those in the high genetic risk group and 
was 1.3% (95% CI, 0.6%-1.9%) in all others. This translates to a NNT to prevent one coronary 
event of 28 (95% CI, 20-50) in the high genetic risk score group and of 80 (95% CI, 52-175) in 
all others. 
 We tested if individuals at high genetic risk for CHD were more predisposed to 
developing subclinical atherosclerosis. Baseline characteristics of the CARDIA Study (ages 32-
47 years at the time of CAC ascertainment) and the BioImage Study (ages 55-80 years) are 
presented in Supplementary Table 6. In CARDIA, for every standard deviation increase in 
polygenic risk score, the multi-variable adjusted odds ratio for CAC presence was 1.32 (95% CI, 
1.04-1.68; P = 0.02) (Table 4).  
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 In BioImage, for every standard deviation increase in polygenic risk score, there was a 
9.7% increase (95% CI, 2.2% to 17.8%; P =0.01) in carotid artery plaque burden. The median 
carotid plaque burden among those at high genetic risk was 215 mm2 (IQR, 52 mm2 to 618 mm2) 
compared to 208 mm2 (IQR: 39 mm2 to 581 mm2) among all other participants (P = 0.02) 
(Supplementary Table 7, Supplementary Table 8). Unlike this expanded 57-SNP score, we 
did not observe an association of a prior restricted 27-SNP score5 with carotid artery plaque 
burden (Supplementary Table 9).  
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DISCUSSION 
Among men with hyperlipidemia enrolled in a randomized controlled trial of primary prevention 
of CHD, statin therapy conferred greater relative benefit among those at high genetic risk when 
compared with all others. Relative risk reduction with statin therapy was 46% in those at high 
genetic risk and 26% among all others; this greater relative benefit was seen despite similar 
levels of LDL lowering by statin therapy in the high genetic risk subgroup compared to all 
others. Additionally, an expanded 57-SNP score was associated with subclinical atherosclerosis 
in two vascular beds. 
 These results permit several conclusions. First, on average, prior trials have shown that 
degree of LDL cholesterol lowering linearly associates with degree of coronary event risk 
reduction;22, 23 however, our data suggests that statins might confer greater relative risk reduction 
in one subgroup - those at high genetic risk. Across three primary prevention trials, those at high 
genetic risk have a nearly three-fold lower number needed to treat to prevent one CHD event. In 
those at high genetic risk, the lower number needed to treat to prevent one CHD event is driven 
by both an elevated baseline rate of events (1.6-fold greater) as well as a greater relative risk 
reduction of events from statin therapy. 
 Large-scale genetic association analyses have expanded the number of SNPs associated 
with CHD.14, 16 Compared to initial reports,24, 25 polygenic risk scores using expanded sets of 
SNPs show improved discrimination for incident CHD events.17, 26 We now show that, in the 
setting of hyperlipidemia, the 57-SNP score remains associated with incident CHD in those with 
or without a self-reported family history of CHD. Furthermore, although the 57-SNP score does 
not associate LDL cholesterol level or extent of LDL cholesterol lowering from statins, those 
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with the highest scores still are more likely to experience clinical benefit among those with at 
least moderate hyperlipidemia. 
 Second, young and middle-aged asymptomatic individuals at high genetic risk for CHD 
have a greater burden of subclinical atherosclerosis. An increased number of CHD variants is 
linked to subclinical atherosclerosis in two vascular beds even after accounting for traditional 
cardiovascular risk factors. We recently demonstrated a step-wise increase in CAC among 
middle-aged asymptomatic adults in BioImage.27 We now extend these findings to a low-risk 
young cohort of essentially statin-ineligible individuals.  
CAC and carotid plaque are both strong predictors of CHD events independent of 
traditional risk factors.12, 28, 29 Subclinical atherosclerosis is a highly heritable trait.30, 31 We and 
others showed that the genetic architectures of CHD and subclinical coronary atherosclerosis are 
highly concordant.32-35 Non-coding genomic variants at 9p21 and 6p24 are strongly associated 
with both CAC and CHD but do not appear to be associated with traditional risk factors.14, 32, 35 
Furthermore, CHD polygenic risk score is strongly associated with CAC in both a cohort with 
the presence of traditional risk factors (BioImage)27 and a younger cohort with a paucity of 
traditional risk factors (CARDIA). This indicates that lifelong exposure to CHD risk alleles 
predisposes to both the development of subclinical and clinical atherosclerosis. The association 
with subclinical atherosclerosis burden may highlight a potential reason why those at high 
genetic risk derive enhanced clinical benefit from primary preventive statin therapy.  Further 
study is required to compare genetic versus atherosclerosis imaging markers to refine decision-
making for initiation of primary preventive therapy with statins. 
 Third, increased CHD risk conferred by genetics seems to be modifiable. We recently 
showed that adherence to a healthy lifestyle27 can modify high genetic risk and now, demonstrate 
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that statin therapy may modify risk as well. Overall, these data may contribute to the 
conversation regarding statin eligibility in the primary prevention setting. Currently, statin 
eligibility is determined based on an estimation of absolute 10-year risk from demographic and 
clinical parameters. Age remains the key determinant of cardiovascular risk estimation.36 High 
genetic risk may identify statin candidates to prevent a first myocardial infarction event who 
otherwise would not have been considered by clinical criteria, a hypothesis that can be tested in 
more contemporary cohorts with sizeable proportions of statin-ineligible patients. Furthermore, 
disclosure of genetic risk may motivate greater adherence with statin therapy.37 
 Our analyses have potential limitations. First, the entry criteria in the three randomized 
controlled trials were different with varying follow-up times. However, there was no significant 
heterogeneity in effect estimates in the genetic risk groups across clinical trials. Second, our 
analyses were performed on individuals of European ancestry. The genetic determinants of CHD 
and their effects on statin benefit in other ancestries may be different.38, 39. Third, in the 
WOSCOPS trial, we included events beyond trial cessation. However, likely crossover occurring 
after the termination of the trial would bias results to the null. Finally, the polygenic risk score 
captures common genetic variation, but about 1 in 200 individuals are affected by a monogenic 
disease, namely familial hypercholesterolemia, that markedly increases risk for CHD.40, 41 The 
clinical utility of a polygenic risk score in those with familial hypercholesterolemia is uncertain. 
 A key goal of precision medicine is to identify subsets of individuals more likely to have 
clinical benefit from preventive strategies. We show that a 57-SNP polygenic risk score for CHD 
can identify individuals 1) at higher risk for developing a coronary event, 2) more likely to 
experience clinical benefit from preventive statin therapy, and 3) with a greater burden of 
subclinical atherosclerosis.  
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Figure Legends 
Figure 1. Incident Coronary Heart Disease Events by Statin Therapy and Genetic Risk 
Group in WOSCOPS 
Nonfatal myocardial infarction or death from coronary heart disease rate by randomized 
treatment group and polygenic risk group in the WOSCOPS trial. Absolute events (and 
percentage) per individuals in each group is shown at the bottom of the bars. This represents 604 
events over 64,031 total patient-years of follow up. The follow up period was 4.8 years (SD 0.7 
years) within the trial for both placebo and statin groups, and out of trial was 8.1 years (SD 3.4 
years) in the placebo group and 8.4 years (SD 3.0 years) in the statin-treated group. 
 
Figure 2. Forest Plot of Incident Coronary Heart Disease After Statin Therapy by Genetic 
Risk Group in Statin Primary Prevention Trials 
The multi-variable adjusted hazard ratios of incident coronary heart disease after statin therapy 
by genetic risk group are presented for three primary prevention trials. Data from JUPITER and 
ASCOT-LLA were obtained from prior analyses.5 Fixed effects meta-analysis was used to 
estimate the relative effect of statin therapy on incident coronary heart disease across trials for 
each genetic risk group (P for difference = 0.05). CI = confidence interval; HR = hazard ratio.  
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Table 1. Characteristics of WOSCOPS Participants by Genetic Risk Group 
 
 High Genetic Risk 
(80th percentile 
polygenic risk score) 
(n = 979) 
All Others 
(<80th percentile 
polygenic risk score) 
(n = 3,913) 
P 
Age, years 54.9 (5.5) 55.2 (5.5) 0.17 
Male, % 100 100 - 
BMI, kg/m2 26.1 (3.1) 26.0 (3.2) 0.35 
Family history of CHD, % 7 5 0.004 
Smoking, % 40 45 0.006 
Diabetes mellitus, % 1 1 0.61 
Systolic blood pressure, mmHg 135.6 (17.1) 135.5 (17.3) 0.95 
Antihypertensive therapy, % 15 14 0.38 
Total cholesterol, mg/dl 272 (22.9) 272 (22.6) 0.74 
LDL cholesterol, mg/dl 192 (17.5) 192 (17.3) 0.20 
HDL cholesterol, mg/dl 44 (9.5) 44 (9.4) 0.41 
Triglycerides, mg/dl 160 (70.0) 160 (66.8) 0.92 
Statin, % 48 51 0.11 
Follow Up, years 13.6 (2.8) 13.6 (2.7) 0.49 
Follow Up within trial, years 4.9 (0.7) 4.8 (0.7) 0.17 
Follow Up after trial, years 8.7 (2.6) 8.3 (2.5) 0.25 
Values are presented as mean (standard deviation) or %. High genetic risk is defined as the top quintile of polygenic 
risk score. Differences between continuous variables were tested with Student t-tests and categorical variables with 
chi-square tests. 
BMI = body-mass index; CHD = coronary heart disease; HDL = high-density lipoprotein; LDL = low-density 
lipoprotein.  
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Table 2. Incident CHD event risk, LDL cholesterol lowering and relative risk reduction of 
CHD across quintiles of polygenic risk score in WOSCOPS 
 
Polygenic 
risk score 
quintile 
CHD event risk* 
HR (95% CI, P) 
LDL cholesterol 
reduction after statin 
mean mg/dl (SD) 
Relative risk reduction with 
statin therapy within each 
quintile of polygenic risk 
HR (95% CI, P) 
Q1 - -44.7 (1.8) 0.65 (0.44-0.97, P =0.035) 
Q2 0.83 (0.57-1.20, P =0.33) -44.8 (1.7) 1.00 (0.67-1.48, P =0.99) 
Q3 1.22 (0.86-1.71, P =0.26) -43.4 (1.8) 0.68 (0.48-0.97, P =0.04) 
Q4 1.06 (0.74-1.51, P =0.77) -43.7 (1.7) 0.77 (0.54-1.11, P =0.16) 
Q5 (High) 1.66 (1.21-2.29, P =0.0019) -42.5 (1.8) 0.56 (0.40-0.78, P <0.001) 
Adjusted for age, sex, diabetes mellitus status, smoking status, LDL cholesterol, HDL cholesterol, systolic blood 
pressure, antihypertensive medication status, and family history of CHD. 
CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio; Q = quintile 
* Placebo-treated participants  
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Table 3. Coronary heart disease event rates by genetic risk and treatment allocation 
 
Trial / 
Polygenic risk 
score 
subgroup 
Placebo Statin Treated 
ARR 
(%) 
NNT 
Events 
(n) 
Individuals 
(n) 
Event 
rate (%) 
Events 
(n) 
Individuals 
(n) 
Event 
rate (%) 
WOSCOPS (604 events, 8.1 years of follow-up) 
All Others 248 1,929 12.9% 201 1,981 10.1% 2.7% 38 
High 100 511 19.6% 55 471 11.7% 7.9% 13 
JUPITER (108 events, 2.4 years of follow-up) 
All Others 53 3,486 1.5% 35 3,483 1.0% 0.5% 200 
High 14 864 1.6% 6 878 0.7% 0.9% 112 
ASCOT-LLA (149 events, 6.1 years of follow-up) 
All Others 61 1,619 3.8% 45 1,756 2.6% 1.2% 84 
High 28 426 6.6% 15 418 3.6% 3.0% 34 
ARR = absolute risk reduction; NNT = number needed to treat with statin to prevent one event. 
JUPITER and ASCOT-LLA data from Mega J*, Stitziel NO*, et al. Lancet. 20155 
* Denotes equal contribution  
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Table 4. CAC burden by polygenic risk score quintile in CARDIA 
 
Polygenic 
risk score 
quintile 
CAC > 0 
% 
CAC > 0 
OR (95% CI, P) * 
Q1 8.7 1 
Q2 12.1 2.08 (0.89-4.83, P =0.09) 
Q3 10.9 2.08 (0.87-4.98, P =0.10) 
Q4 14.3 3.02 (1.31-7.00, P =0.01) 
Q5 (High) 15.6 2.51 (1.08-5.85, P =0.04) 
* Relative to Q1. Adjusted for age, sex, diabetes mellitus status, smoking status, LDL cholesterol, HDL cholesterol, 
systolic blood pressure, antihypertensive medication status, and family history of CHD 
CAC = coronary artery calcification; CHD = coronary heart disease; CI = confidence interval HR = hazard ratio; 
PCE = Pooled Cohorts Equation; PRS = polygenic risk score; Q = quintile  
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Figure 1. Incident Coronary Heart Disease Events by Statin Therapy and Genetic Risk 
Group in WOSCOPS 
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Figure 2. Forest Plot of Incident Coronary Heart Disease After Statin Therapy by Genetic 
Risk Group in Statin Primary Prevention Trials 
 
